Ligustilides: A Comprehensive Reference
1. Identity and Chemical Nature
Ligustilide is a natural chemical compound of the dihydrophthalide class. Its systematic IUPAC name is 3-butylidene-4,5-dihydro-3H-isobenzofuran-1-one, and it is most commonly encountered in nature as the geometric isomer (Z)-ligustilide (also written Z-ligustilide). The major phthalides Z-ligustilide and Z-butylidenephthalide (3-butylidene-3H-isobenzofuran-1-one) are common phytoconstituents of the Apiaceae family.
Ligustilide has the molecular formula C12H14O2 and is characterized by its high lipophilicity, favorable blood-brain barrier permeability, and multi-target pharmacological activity. The compound belongs to the broader structural class of phthalide lactones; all naturally occurring phthalides are derived from 1(3H)-isobenzofuranone, consisting of one benzene ring bonded with a γ-lactone between carbon atoms, with the most simple phthalide structure having the formula C8H6O2.
Ligustilide is a volatile compound found in the essential oil of various herb roots. In isolated form, it appears as an oil. While it has been associated with a variety of observed biological effects, it is also known for its instability and rapid chemical degradation. This chemical lability is a defining characteristic that has significant implications for its research and potential therapeutic use.
1.1 Botanical Sources
Ligustilide is a dihydrophthalide and an active ingredient of umbelliferous plants such as Angelica sinensis and Ligusticum chuanxiong, having a wide range of pharmacological effects. Its distribution across the plant kingdom is broader, however:
- Angelica sinensis (Dong quai / Chinese angelica): The volatile oil is one of the main effective components of A. sinensis, and ligustilide is the most abundant component in the volatile oil, accounting for approximately 60%.
- Ligusticum chuanxiong (Chuanxiong / Szechuan lovage): The dried roots are used as medicinal items; widely grown in China and Asia, the chief chemicals include ligustilide and senkyunolides.
- Apium graveolens (Wild celery): Ligustilide is found in the highest concentration in wild celeries (Apium graveolens).
- Other Apiaceae species: It has also been found in Angelica sinensis and a variety of other plants including Todaroa montana. The compound is broadly characteristic of the Apiaceae (Umbelliferae) family, which also includes Ligusticum porteri (Osha), Angelica acutiloba, and Angelica tenuissima.
1.2 Common Forms and Preparations
Ligustilide as an isolated compound is not widely available as a standalone dietary supplement; it is instead consumed indirectly through preparations of its source herbs. Dong quai is normally taken orally as pills, tablets, decoctions, and tinctures. In research contexts, cyclodextrin complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) has been shown to markedly improve bioavailability; the absolute bioavailability of ligustilide in rats treated with the HP-β-CD complex was 35.9% compared to 7.5% for ligustilide alone, representing a relative improvement of approximately 530%. Novel delivery systems including liposomal encapsulation are also under preclinical investigation to overcome the compound's inherent instability.
2. Traditional and Historical Use
2.1 Traditional Chinese Medicine (TCM)
Because of the traditional use of Angelica sinensis in herbal medicine, particularly traditional Chinese medicine where it is known as dong quai, there has been significant interest in identifying the chemical compounds responsible for its putative pharmacological effects. Ligustilide is typically identified as the principal bioactive component.
Ligusticum sinense (in older literature L. wallichii or L. chuanxiong) is one of the 50 fundamental herbs used in Chinese herbology, where it is called chuānxiōng (川芎), known in English as Szechwan lovage. Its roots and rhizomes, commonly known as "Chuan Xiong" in TCM, have played a vital role in herbal remedies since ancient times; historical records reveal that Ligusticum was highly regarded for its ability to invigorate blood circulation, dispel wind, and relieve pain, making it a staple in addressing ailments ranging from headaches, menstrual disorders, and rheumatism to cardiovascular conditions.
Ligusticum started to become known as a popular herb used against "blood stagnation" in TCM. Angelica sinensis has a long history of use in traditional herbal medicine and is traditionally used for treating female disorders including irregular menstruation, amenorrhea, and osteoporosis.
A key classical multi-herb formula containing Chuanxiong is the Si Wu Tang (Four-Substance Decoction). In Chinese herbalism, Chuanxiong is a principal ingredient in the "Four-Substance Decoction" (Si Wu Tang) for women's health, and is often paired with Angelica sinensis (Dong Quai) for synergistic blood-nourishing effects. Another classical formula, Fo Shou San (FSS), is composed of Chuanxiong Rhizoma (major constituent Z-ligustilide) and Angelicae Sinensis Radix (major component ferulic acid) with a Z-ligustilide:ferulic acid ratio of 2:3, and was used in TCM to treat hypertension.
2.2 Native American Herbal Tradition
Ligustilide is contained in high concentrations in plants from Chinese and Native American traditional medicine. In the Western herbal tradition, Ligusticum porteri (Osha root) is the primary ligustilide-containing herb. L. porteri (osha) is used in Western herbal medicine. Osha root extracts are also traditionally used for preventing cold and flu, treating symptoms of acute influenza, bronchial pneumonia, and leukocytosis; although clinical trials have not shown effectiveness of osha root extract in preventing cold and flu, both in vitro and in vivo animal studies have demonstrated anti-inflammatory and antioxidant properties.
2.3 Japanese Kampo Medicine
Angelica acutiloba, a traditional Chinese and Japanese herbal medicine, has been used medicinally in East Asia. In the Japanese Kampo system, Angelica acutiloba (known as Toki) serves a role analogous to Angelica sinensis in Chinese medicine, and ligustilide is among its primary bioactive constituents.
3. Key Constituents and Co-occurring Compounds
Ligustilide does not occur in isolation in its source plants; it is part of a complex phytochemical matrix. Ligusticum chuanxiong has long been used as a traditional Chinese medicine in folk remedies; its major chemical components include essential oil (EO), alkaloids, phenolic acids, phthalide lactones, and other constituents, which display vasorelaxation, anti-inflammation, antioxidant, antiproliferation, and other activities in both in vitro and in vivo studies.
The most important co-occurring compounds in its principal source plants include:
- Senkyunolides (A, H, I): Other phthalide lactones co-occurring with ligustilide in Chuanxiong. The lactone component of Ligusticum chuanxiong mainly contains Z-ligustilide, senkyunolide A, senkyunolide H, and senkyunolide I.
- Ferulic acid: A phenolic acid found alongside ligustilide in Angelica sinensis and in the classical formula Fo Shou San.
- Tetramethylpyrazine (TMP): Key constituents of Ligusticum include the alkaloid tetramethylpyrazine, ferulic acid (a phenolic compound), chrysophanol, sedanoic acid, and essential oils including ligustilide and butylphthalide.
- Z-butylidenephthalide: Both phthalides (Z-ligustilide and Z-butylidenephthalide) have been shown to be associated with a variety of bioactivities such as vasodilative, anti-atherosclerotic, and anticonvulsive effects, and are known to be unstable compounds.
- 3-Butylphthalide: Multiple phthalides have been identified in celery including phthalide, 3-butylphthalide, 3-butylidenephthalide, (Z)-ligustilide, and sedanenolide.
4. Pharmacology: Mechanisms of Action
Research has identified multiple molecular targets and pathways through which ligustilide exerts its biological effects. The breadth of these mechanisms is consistent with a multi-target natural product acting on fundamental cellular stress-response pathways.
4.1 Modulation of Oxidative Stress: Nrf2/ARE Pathway
Ligustilide promotes activation (nuclear translocation) of Nrf2 and induction of its antioxidant pathway, including expression of the target gene HO-1. Ligustilide has anti-inflammatory and antioxidant activity through the induction of Klotho and the Nrf2 antioxidant system. This pathway represents one of the cell's primary defenses against oxidative damage and is implicated in ligustilide's neuroprotective effects.
4.2 Anti-inflammatory Signaling: NF-κB and MAPK Pathways
In lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages, (Z)-ligustilide strongly inhibits the induction of LPS-induced inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at both the mRNA and protein levels in a dose-dependent manner; the transcriptional activity of NF-κB was also downregulated in a concentration-dependent manner; further study revealed that (Z)-ligustilide inhibited the phosphorylation and subsequent degradation of IκBα, an inhibitor protein of NF-κB. In addition, ligustilide has been found to reduce the production of pro-inflammatory cytokines such as TNF-α and IL-1β in primary cultured microglia induced by LPS and to inhibit the expression of COX-2, iNOS, and IL-6.
4.3 TRPA1 Channel Modulation
Ligustilide, contained in high concentrations in plants from Chinese and native American traditional medicine, has been identified as a potent TRPA1 agonist, with only marginal inhibitory activity on dural application of mustard oil-activated currents. Research published in Pflügers Archiv demonstrated that ligustilide shows bimodal sensitivity at TRPA1 channels. As a covalent activator of anti-oxidant response via Nrf2 and of TRPA1-associated sensory responses, ligustilide seems to act as a biological analogue of mustard oil, despite the very different profile of in vivo activities. This TRPA1 interaction is relevant to understanding its analgesic and sensory modulatory properties.
4.4 Cardiovascular Mechanisms: Vasorelaxation
Ligustilide can inhibit the proliferation of and cell cycle progression of vascular smooth muscle cells and inhibits vasoconstriction; it increases vasodilation, anti-thrombosis, and serotonergic activity and decreases platelet aggregation. At the molecular level, ligustilide induces vasodilatation via inhibiting voltage-dependent calcium channels and receptor-mediated Ca2+ influx and release. Both ligustilide and senkyunolide A had similar relaxation potencies against multiple contractile stimuli in rat isolated aorta; their vasorelaxation effects were not affected by endothelium removal, suggesting a smooth muscle-directed mechanism.
4.5 Neuroprotective Signaling Cascades
Ligustilide's mechanisms of neuroprotection mainly involve modulation of PI3K/Akt, MAPK, NF-κB, Nrf2/ARE, AMPK, and other signaling pathways, leading to reduced oxidative stress, inflammation, apoptosis, and mitochondrial dysfunction. In Parkinson's disease models specifically, Z-ligustilide alleviates oxidative stress-induced apoptosis of microglia by triggering the endogenous antioxidant system; it also modulates phenotypic polarization of microglia through activation of the Nrf2-TrxR axis, leading to microglia polarization towards the M2 phenotype.
4.6 Uterine Smooth Muscle Relaxation
It has been postulated that the antispasmodic effects of dong quai are related to the volatile oil constituents ligustilide, butylidenephthalide, and butylphthalide, while the uterine-stimulant effect is due to the water-soluble components. In isolated rat uterine preparations, ligustilide has been shown to inhibit spontaneous periodic contractions through calcium channel-related mechanisms, providing a plausible mechanistic basis for its traditional use in dysmenorrhea.
4.7 Senolytic Activity
A 2024 study published in Advanced Biology reported a newly identified mechanism: ligustilide—an alkylphthalide found in Angelica acutiloba—decreased both senescent cell viability and SA-β-Gal activity; it also enhanced cleaving of caspase-3 and Bcl-xL (an anti-apoptotic protein), and reduced the production of SASP inflammatory cytokine IL-6. This senolytic activity — the selective killing of senescent cells — positions ligustilide as a candidate for investigation in aging-related research.
5. Scientific Evidence by Area of Use
The vast majority of evidence for ligustilide consists of in vitro cell studies and animal models. Human clinical evidence is extremely limited and, where it exists, was typically obtained with whole-herb preparations rather than isolated ligustilide. This distinction is noted throughout each section.
5.1 Ischemic Stroke and Cerebrovascular Protection
This is the most extensively investigated area in preclinical research. A 2025 systematic review and meta-analysis published in a peer-reviewed journal provides the highest-level preclinical synthesis available:
The pooled results from 13 studies demonstrated that ligustilide significantly reduced infarct volume (SMD = 3.26, 95% CI [2.31, 4.22], P < 0.05) and improved neurological scores (SMD = 1.64, 95% CI [1.13, 2.15], P < 0.05) in animal models of ischemic stroke compared to control groups. Mechanistically, ligustilide exerted protective effects by alleviating oxidative stress (lowering MDA levels and enhancing SOD and GSH levels), suppressing inflammatory responses (reducing TNF-α), and a non-significant trend toward reduced apoptosis was also noted based on TUNEL staining. Subgroup analyses indicated that heterogeneity might be associated with differences in modeling methods, administration routes, and the use of multiple intervention doses.
Earlier animal work showed that in experimental models of middle cerebral artery thrombosis in the rat, Ligustricum was found to reduce the infarct area, limit the extent of cerebral thrombosis, and induce general vascular dilatation. Z-ligustilide exerted significant neuroprotection against cerebral ischemic damage in several animal models.
Evidence strength: Preclinical only. No human clinical trials specifically examining isolated ligustilide for stroke outcomes have been published. Clinical applications of ligustilide remain limited, and comprehensive preclinical evidence regarding its efficacy and mechanisms of action is still being clarified.
5.2 Neurodegeneration: Alzheimer's Disease
A substantial body of animal and cell-line research has examined ligustilide's effects on Alzheimer's disease (AD) pathology.
The natural phthalide ligustilide has been demonstrated to protect against aging- and amyloid-β (Aβ)-induced brain dysfunction in animal models; in AD double-transgenic (APP/PS1) mice and cultured human cells, ligustilide significantly ameliorated memory impairment and Aβ levels and plaque burden; specifically, it appeared to act as a potent enhancer of α-secretase (ADAM10), leading to upregulation of alpha-processing of both APP and Klotho with inhibition of IGF-1/Akt/mTOR signaling.
A study using liposome-encapsulated ligustilide found that liposome-packaged ligustilide (LIG-LPs) treatment reduced oxidative stress and β-amyloid (Aβ) deposition and mitigated cognitive impairment in APP/PS1 mice; LIG management alleviated the destruction of the inner structure in hippocampal mitochondria and ameliorated the imbalance between mitochondrial fission and fusion in the APP/PS1 mouse brain. In an accelerated aging mouse model (SAMP8), behavioral tests including the Morris water maze, object recognition task, open field test, and elevated plus maze showed that ligustilide could improve memory deficit in SAMP8 mice; ligustilide decreased P-Drp1 (fission) and increased Mfn1 and Mfn2 (fusion) levels, and also increased P-AMPK and ATP levels.
Evidence strength: There have been no human studies examining the efficacy of ligustilide for dementia prevention; rodent studies have provided evidence of its neuroprotective capabilities. Due to its poor stability and bioavailability profile, novel formulations of ligustilide would need to be developed in order for it to be a viable option for testing in clinical trials.
5.3 Neurodegeneration: Parkinson's Disease
A 2024 study published in PMC investigated Z-ligustilide in an MPTP-induced Parkinson's disease mouse model. The results showed that Z-ligustilide attenuated motor deficits in mice and prevented the loss of dopaminergic neurons in the substantia nigra. The underlying mechanism involved alleviation of oxidative stress-induced apoptosis of microglia by triggering the endogenous antioxidant system, and modulation of microglial phenotypic polarization through activation of the Nrf2-TrxR axis, leading to M2 polarization.
Evidence strength: Preclinical (animal model) only. No human clinical data available.
5.4 Vascular Dementia
A 2022 study in Metabolic Brain Disease used a bilateral common carotid artery occlusion rat model to investigate ligustilide at doses of 20 or 40 mg/kg/day (orally for four weeks). Morris water maze testing showed that ligustilide effectively ameliorated learning and memory impairment in VaD rats; ligustilide obviously reduced neuronal oxidative stress damage and the level of homocysteine in the brain of VaD rats. Mechanistically, experimental studies have shown that ligustilide can alleviate cognitive dysfunction and brain injury induced by chronic ischemia, partly through enhancement of antioxidant capacity and improvement of cholinergic system activity; beyond its antioxidative effects, ligustilide also protects hippocampal neuronal structure and dendritic integrity by suppressing neuronal apoptosis and abnormal astrocyte proliferation in VaD models.
Evidence strength: Preclinical (animal model) only. No human clinical evidence.
5.5 Cardiovascular Disease: Atherosclerosis and Platelet Function
Recent studies have shown that the lactone component of Ligusticum chuanxiong possesses therapeutic effects including anti-atherosclerotic, vasorelaxation, and anti-inflammatory actions. Regarding platelet function, Z-ligustilide has been shown to decrease platelet aggregation induced by ADP ex vivo and to reduce arteriovenous shunt thrombosis in vivo in rats. With respect to vascular smooth muscle cells, ligustilide reduces VSMC migration in the treatment of atherosclerosis, acts as an anti-inflammatory agent, and prevents excessive cell proliferation and migration.
The formula Fo Shou San (FSS) stimulated eNOS-derived NO bioavailability via the PKB/Akt signaling pathway, increased intracellular Ca2+, reduced ROS generation, and inhibited ACE. Korean research found that the combination of Ligusticum wallichii and Angelica gigas elicited a synergistic effect on vasorelaxation in isolated rat aortas and antihypertension in spontaneously hypertensive rats.
Evidence strength: Primarily in vitro and animal studies. Clinical data for isolated ligustilide is absent; multi-ingredient TCM formulas have been studied but results cannot be attributed to ligustilide alone.
5.6 Menstrual Disorders and Women's Health
Butylidenephthalide and ligustilide have, in vitro, an inhibitory effect on uterine muscle contractions. This spasmolytic action on uterine smooth muscle provides mechanistic support for the traditional use of ligustilide-containing herbs in dysmenorrhea.
Clinical evidence for whole-herb preparations is limited in quality. Reviews suggest evidence for effect in dysmenorrhea exists from studies of dong quai; however, the studies included were of short duration and low quality. Some clinical evidence shows that dong quai improves menopausal symptoms when used in combination with other ingredients; in one clinical trial, daily intake of a specific combination containing dong quai and chamomile for 12 weeks reduced the frequency and severity of hot flashes in menopausal women compared with placebo; however, it is unknown whether this beneficial effect was due to dong quai, another ingredient, or the combination.
Evidence strength: The spasmolytic mechanism is supported by in vitro data. Clinical evidence comes from multi-ingredient preparations only and is of low quality; no clinical trials of isolated ligustilide for women's health outcomes have been conducted.
5.7 Bone Health and Osteoporosis
A PMC-published study from 2019 examined ligustilide's effect on bone formation. The results showed that ligustilide significantly ameliorated inhibition of bone formation in zebrafish caused by prednisolone; ligustilide promoted osteoblast differentiation, including that of the pre-osteoblastic cell line MC3T3-E1 and bone marrow mesenchymal stem cells; ligustilide greatly improved the viability of MC3T3-E1 cells exposed to H2O2, attenuated H2O2-induced apoptosis and increased expression of Bcl-2. Furthermore, ligustilide treatment led to marked activation of phosphorylated EGFR and ERK1/2; these effects could be obviously inhibited by blocking GPR30 signaling with the specific inhibitor G15; collectively, the results reveal that GPR30 is a positive switch for ligustilide to increase bone formation via regulation of EGFR.
Evidence strength: Preliminary, zebrafish and cell-line only. No clinical data.
5.8 Anticancer Activity
A comprehensive 2025 review published in Pharmaceuticals (MDPI) summarized the oncological research. Ligustilide and its geometric isomer (Z)-ligustilide represent promising phytochemicals with notable anticancer potential across a spectrum of malignancies; preclinical evidence demonstrates that both compounds exhibit potent antitumor activity through multiple, often complementary mechanisms including apoptosis induction, autophagy modulation, inhibition of cell proliferation, and modulation of oncogenic signaling pathways; overall, the evidence indicates that ligustilide exhibits broader anticancer activity across multiple solid tumors—particularly gastric, bile duct, bladder, liver, and osteoblastoma cancer. A cell study also found that ligustilide may serve as a potential anticancer agent by reversing T-cell inhibition by cancer-associated fibroblasts (CAFs).
Evidence strength: Despite promising preclinical results, the precise molecular mechanisms, pharmacokinetics, and bioavailability of ligustilide remain under investigation. All evidence is preclinical (in vitro / animal). No human oncology trials have been conducted with isolated ligustilide.
5.9 Anti-inflammatory Effects
Ligustilide's anti-inflammatory activity has been one of the most consistently demonstrated effects across experimental systems. Experiments have shown that ligustilide at a dosage of 20 mg/kg/day is effective in reducing inflammation, as evidenced by its reduction of proinflammatory cytokines including TNF-α, IL-1β, vascular endothelial growth factor-α, and IL-17 in endotoxin-infected mice within 24 hours.
Evidence strength: Well-characterized in vitro and animal data; no human clinical evidence for the anti-inflammatory effects of isolated ligustilide.
5.10 Traumatic Brain Injury
Ligustilide, a natural compound with excellent blood-brain barrier (BBB) penetration, shows great potential in neuroprotection, primarily due to its anti-inflammatory, antioxidant, and pro-autophagic properties. Animal studies in aged TBI mice showed that ligustilide attenuated microglial-mediated neuroinflammation and improved behavioral outcomes. Current evidence indicates that ligustilide exerts neuroprotective effects in multiple CNS disorders, including ischemic stroke, cerebral ischemia–reperfusion injury, vascular dementia, Alzheimer's disease, Parkinson's disease, traumatic brain injury, and anxiety disorders.
Evidence strength: Preclinical (animal) only. No human data.
6. Pharmacokinetics and Bioavailability
The pharmacokinetic profile of ligustilide demonstrates rapid absorption and elimination, with low oral bioavailability primarily due to extensive first-pass metabolism and its structural instability.
Key pharmacokinetic parameters from rat studies include:
- Oral bioavailability: Z-ligustilide was rapidly absorbed by rats after oral administration, although the bioavailability was very low (2.6%); after oral administration of 500 mg/kg body weight, plasma Cmax was 0.66 μg/mL at a tmax of approximately 0.36 h.
- First-pass metabolism: Pharmacokinetic studies have shown that Z-ligustilide has poor oral bioavailability in rats due to severe first-pass metabolic reactions.
- Metabolic enzymes: Available preclinical data indicate that ligustilide undergoes rapid metabolism; CYP3A4, CYP2C9, and CYP1A2 may mediate this metabolism.
- Blood-brain barrier: Available studies suggest that ligustilide can cross the blood-brain barrier and shows relatively favorable safety in preclinical models.
- Structural instability: Its inherent structural instability and very low bioavailability—with degradation half-lives of only minutes to a few hours in the rat—contribute substantially to formulation challenges.
- Cyclodextrin complexation: The oral bioavailability of ligustilide in rats was only 2.6%; cyclodextrin complexation improved bioavailability. HP-β-CD complexation increased absolute bioavailability to 35.9%.
7. Dosage Forms and Reported Dosages
Ligustilide is not available as a pharmaceutical-grade isolated compound in mainstream clinical practice. The dosages below are drawn exclusively from preclinical studies and are presented strictly as reported in those sources:
- Vascular dementia (rat model): In a bilateral common carotid artery occlusion rat model, ligustilide (20 or 40 mg/kg/day) and nimodipine (20 mg/kg) were orally administered to VaD rats for four weeks.
- Anti-inflammatory (animal): Ligustilide at a dosage of 20 mg/kg/day was shown effective in reducing proinflammatory cytokines in endotoxin-infected mice within 24 hours.
- Uterine contraction (in vitro): Concentrations of 2–8 μg/mL inhibited spontaneous periodic contractions in isolated rat uterine preparations.
- Whole-herb preparations: Dong quai is normally taken orally as pills, tablets, decoctions, and tinctures. Standardized dosage guidance for ligustilide content in commercial herb preparations is not established in authoritative pharmacopeial monographs reviewed in the preparation of this article.
8. Safety Considerations and Drug Interactions
8.1 General Toxicity Profile
Although ligustilide is a natural bioactive compound isolated from traditional medicinal herbs and is generally considered to exhibit favorable biocompatibility and relatively low toxicity, excessive exposure may still induce adverse biological effects; therefore, its safety profile and potential toxicological risks have attracted increasing attention; acute toxicity studies have demonstrated that ligustilide possesses relatively low toxicity. While preliminary evidence suggests a relatively benign safety profile, the absence of systematic toxicological evaluation remains a significant limitation and warrants dedicated investigation.
8.2 Instability and Degradation
A unique and important safety consideration is that ligustilide itself may not be the final biologically active entity in all preparations. Because of the chemical instability of ligustilide, the relevance of in vitro studies to any effects in humans is uncertain. The compound degrades rapidly under ambient conditions, forming a complex mixture of dimers and other degradation products, which means that the actual active constituents of heat-processed decoctions may differ substantially from those present in fresh root preparations.
8.3 CYP Enzyme Interactions
Ligustilide undergoes rapid metabolism and is metabolized by CYP3A4, CYP2C9, and CYP1A2. This is pharmacologically significant because compounds metabolized by these enzymes can potentially compete with or alter the metabolism of co-administered drugs that use the same enzymatic pathways. The enzymes that contribute the most to the breakdown of ligustilide and ferulic acid in the body are CYP3A4, CYP1A2, CYP2C8, and CYP2C9; people may be more or less susceptible to dong quai's effects depending on their variants of these enzymes.
8.4 Anticoagulant/Antiplatelet Interactions
Given ligustilide's documented antiplatelet activity, concurrent use of Chinese angelica and warfarin may increase warfarin's anticoagulant effects and increase the risk of bleeding. This interaction has been documented in the context of whole-herb preparations and is pharmacologically plausible for ligustilide given its platelet aggregation-inhibiting properties.
8.5 Hormonal and Estrogenic Considerations
Some research suggests that the root of dong quai is not a phytoestrogen in the classical sense, and the substance may act through an alternative mechanism. The estrogenic status of the plant and its phthalide components, including ligustilide, remains unresolved. Those preparations with the highest ferulic acid or lowest ligustilide content were found to be more estrogenically active in some studies. Although botanicals are perceived as natural safe remedies, it is important to recognize that they have not been rigorously tested for potential toxic effects and/or drug/botanical interactions.
8.6 Photosensitivity
Members of the Apiaceae family, including Angelica species, contain furanocoumarins that are established photosensitizers. This is documented for the genus broadly, though specific attribution to ligustilide has not been established; the risk is associated with whole-plant preparations.
8.7 Pregnancy and Lactation
Use of dong quai during pregnancy or while breastfeeding should be avoided. This guidance is based on the potential effects of the herb's components, including ligustilide's smooth muscle and uterine-contractile modulating properties, on uterine tone.
8.8 Reproductive and Long-term Toxicity Data Gaps
Reproductive and developmental toxicity studies and drug-drug interaction profiling remain to be undertaken; while preliminary evidence suggests a relatively benign safety profile, the absence of systematic toxicological evaluation is a significant limitation.
9. Summary of Evidence Landscape
The therapeutic potential of ligustilide remains largely limited to preclinical studies, and well-designed clinical investigations are still lacking; further studies are needed to evaluate its long-term safety, optimal administration strategies, and clinical efficacy in different CNS disorders.
In the most actively investigated domains — neuroprotection, cardiovascular protection, and anti-inflammation — ligustilide has demonstrated consistent and mechanistically coherent effects across numerous cell and animal studies. However, the compound's profound pharmacokinetic limitations (oral bioavailability of approximately 2.6% in rats, rapid degradation, extensive first-pass metabolism) mean that the biological concentrations needed for the effects observed in vitro may not be achievable in human subjects through conventional oral administration. Novel formulations of ligustilide would need to be developed in order for it to be a viable option for testing in clinical trials. Liposomal, cyclodextrin, and derivative-based strategies are currently being explored in preclinical settings.
References
Go back